CNTXContext Therapeutics Inc.

Nasdaq contexttherapeutics.com


$ 2.33 $ -0.16 (-6.43 %)    

Friday, 09-Aug-2024 13:44:24 EDT
QQQ $ 450.42 $ 4.65 (1.04 %)
DIA $ 395.01 $ 1.46 (0.37 %)
SPY $ 532.43 $ 3.80 (0.72 %)
TLT $ 96.26 $ 0.11 (0.11 %)
GLD $ 224.73 $ -0.10 (-0.04 %)
$ 2.4
$ 2.49
$ 2.32 x 100
$ 2.34 x 100
$ 2.25 - $ 2.49
$ 0.77 - $ 2.54
58,520
na
131.9M
$ 1.65
nm
TBD
na
na ($ 0.00)
na
TBD na
How to Read 10-K & 10-Q Reports To View SEC Filing Reports, Please Register or Sign In
# Filing Date Period End Date Type Report Link
1 08-07-2024 06-30-2024 10-Q
2 05-08-2024 03-31-2024 10-Q
3 03-21-2024 12-31-2023 10-K
4 11-09-2023 09-30-2023 10-Q
5 08-09-2023 06-30-2023 10-Q
6 05-10-2023 03-31-2023 10-Q
7 03-22-2023 12-31-2022 10-K
8 11-09-2022 09-30-2022 10-Q
9 08-11-2022 06-30-2022 10-Q
10 05-11-2022 03-31-2022 10-Q
11 03-23-2022 12-31-2021 10-K
12 12-02-2021 09-30-2021 10-Q
Guide for Analyst Ratings To View Analyst Ratings, Please Register or Sign In
# Date Analyst Firm Upside/Downside Price Target Change Rating Change Current Rating

News

OPINIONS

 context-therapeutics-q2-2024-adj-eps-004-beats-007-estimate

Context Therapeutics (NASDAQ:CNTX) reported quarterly losses of $(0.04) per share which beat the analyst consensus estimate of ...

 hc-wainwright--co-reiterates-buy-on-context-therapeutics-maintains-5-price-target

HC Wainwright & Co. analyst Emily Bodnar reiterates Context Therapeutics (NASDAQ:CNTX) with a Buy and maintains $5 price...

 context-therapeutics-acquires-phase-1-ready-t-cell-engager-ct-95-formerly-owned-by-link-immunotherapeutics-no-terms-disclosed

CT-95, formerly owned by Link Immunotherapeutics, a mesothelin x CD3 T cell engaging bispecific antibody with first-in-class po...

 context-therapeutics-13g-filing-shows-great-point-partners-llc-reported-a-989-stake-in-the-co-as-of-may-31-2024

- SEC Filing

 piper-sandler-initiates-coverage-on-context-therapeutics-with-overweight-rating-announces-price-target-of-45

Piper Sandler analyst Joseph Catanzaro initiates coverage on Context Therapeutics (NASDAQ:CNTX) with a Overweight rating and...

 context-therapeutics-13g-filing-shows-	avidity-partners-management-lp-reported-a-99-stake-in-the-co-as-of-may-2-2024

- SEC Filing

 deep-track-capital-reports-passive-stake-of-989-in-context-therapeutics-as-of-may-2-2024

-SEC Filing

 hc-wainwright--co-maintains-buy-on-context-therapeutics-raises-price-target-to-5

HC Wainwright & Co. analyst Emily Bodnar maintains Context Therapeutics (NASDAQ:CNTX) with a Buy and raises the price ta...

 maxim-group-maintains-buy-on-context-therapeutics-raises-price-target-to-10

Maxim Group analyst Jason McCarthy maintains Context Therapeutics (NASDAQ:CNTX) with a Buy and raises the price target from ...

 context-therapeutics-q1-eps-023-beats-038-estimate

Context Therapeutics (NASDAQ:CNTX) reported quarterly losses of $(0.23) per share which beat the analyst consensus estimate of ...

 hc-wainwright--co-maintains-buy-on-context-therapeutics-lowers-price-target-to-4

HC Wainwright & Co. analyst Emily Bodnar maintains Context Therapeutics (NASDAQ:CNTX) with a Buy and lowers the price ta...

 why-quanex-building-products-shares-are-trading-lower-by-over-10-here-are-other-stocks-moving-in-fridays-mid-day-session

Shares of Quanex Building Products Corporation (NYSE: NX) moved lower during Friday’s session after the company reported fourth...

CLASS ACTION DEADLINES - JOIN NOW!

NEW CASE INVESTIGATION